|
CERVICONC-II-300 study |
07/08/2018 |
CIGB |
|
Quality of Life and safety of the nutritional supplement Deprexil® or Placebo in combination with cognitive stimulation treatment in patients with Mild Cognitive Impairment and Mild Alzheimer's Dementia. |
07/03/2024 |
CATALYSIS |
|
14F7 in chronic B-cell lymphoproliferative syndrome |
07/03/2018 |
CIM |
|
Nasal recombinant human interferon alfa-2b in ARI |
06/12/2022 |
CIGB |
|
Phase II clinical trial, controlled, randomized, double-blind to assess the immunogenicity of live attenuated vaccine candidate against cholera CV638 . |
06/11/2014 |
FINLAY |
|
Transfer factor in Chronic Kidney Disease |
06/08/2020 |
CIGB |
|
Exploratory study to evaluate the effect and safety of CIGB 500 in seriously ill patients with shock |
06/07/2023 |
CIGB |
|
Nimotuzumab cold kit for the immunodiagnosis of solid tumors |
05/10/2018 |
CIM |
|
CIMAbior® in CD20-positive B-cell Non-Hodgkin Lymphoma |
05/09/2017 |
CIM |
|
An Observational Study to Evaluate the Real-World Clinical Management and Outcomes of ALK-Positive Advanced NSCLC Participants Treated With Alectinib |
05/08/2021 |
ROCHE |
|
Lithium Carbonate-COVID-19- mild and moderate -Exploratory / Phase II |
05/08/2021 |
ICBPGirón |
|
Rectal Ozone in the COVID-19 treatment |
05/06/2020 |
CPN |
|
Oncoxin®-Viusid®- Quality of life of patients with metastatic colorectal adenocarcinoma-adults-Phase II |
05/06/2018 |
CATALYSIS |
|
HEBERFERON in renal cell carcinoma |
05/01/2017 |
CIGB |
|
Dose scale-up and cohort expansion with the therapeutic mAb 14F7 |
04/12/2015 |
CIM |
|
Phase III study of the Cuban vaccine candidate VCN7-T in patients from 1 to 18 years of age at risk of pneumococcal disease in Havana |
04/10/2023 |
FINLAY |
|
Vaccine HER1 / VSSP for prostate cancer, head and neck carcinoma and advanced colon cancer . Phase I |
03/11/2017 |
CIM |
|
Study on pneunococcal vaccination in the pediatric population from 1 year to 5 years |
03/08/2023 |
FINLAY |
|
Biomodulina T in pediatric septic shock. Exploratory study |
03/08/2020 |
BIOCEN |
|
HeberNasvac® Phase IV in Chronic Hepatitis B |
03/08/2018 |
CIGB |
